VIldagliptin as an ischemic PERconditioning mimetic agent in Acute Myocardial Infarction - VIPER–AMI trial

• Conditions: ST Elevation Myocardial Infarction; MedDRA version: 17.1Level: PTClassification code 10000891Term: Acute myocardial infarctionSystem Organ Class: 10007541 - Cardiac disorders; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2014-001205-41-PT
• Lead Sponsor: Sociedade Portuguesa de Cardiologia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-10-20
• Last Update Posted: 10 July 2015

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 128

Inclusion Criteria

- = 18 years old
- STEMI presenting < 12h of symptoms
- Both genders
- Diabetic or non-diabetic patients
- Killip I-II class STEMI
- Able to understand and sign an informed consent form
- Females must be non-pregnant and non-lactating
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 93
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 35

Exclusion Criteria

- Killip III-IV class STEMI
- Blood glucose level at admission <60mg/dL
- Previous MI; ACS???
- CKD or AKI at admission with GFR/creatinine clearance estimated to be <30ml/min
- Previous CABG; DPP-IV
- TIMI flow grade >1 on angiography
- Unable to consent;
- Female pregnant or breast feeding;
- History of acute or chronic pancreatitis.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified